Company Overview
flowchart TD
Novartis_AG___Sphingosine_1_Ph["Novartis AG — Sphingosine-1-Phosphate Receptor M"]
Novartis_AG___Sphingosine_1_Ph["Company"]
Novartis_AG___Sphingosine_1_Ph -->|"related to"| Novartis_AG___Sphingosine_1_Ph
style Novartis_AG___Sphingosine_1_Ph fill:#81c784,stroke:#333,color:#000
Novartis_AG___Sphingosine_1_Ph["Swiss"]
Novartis_AG___Sphingosine_1_Ph -->|"related to"| Novartis_AG___Sphingosine_1_Ph
style Novartis_AG___Sphingosine_1_Ph fill:#81c784,stroke:#333,color:#000
Novartis_AG___Sphingosine_1_Ph["multinational"]
Novartis_AG___Sphingosine_1_Ph -->|"related to"| Novartis_AG___Sphingosine_1_Ph
style Novartis_AG___Sphingosine_1_Ph fill:#81c784,stroke:#333,color:#000
style Novartis_AG___Sphingosine_1_Ph fill:#4fc3f7,stroke:#333,color:#000
...Company Overview
Mermaid diagram (expand to render)
Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland, with one of the broadest portfolios in neuroscience. Within the neurodegeneration space, Novartis has pioneered the development of [sphingosine-1-phosphate (S1P) receptor modulators](/mechanisms/sphingolipid-metabolism-neurodegeneration), a class of agents that modulate [ceramide](/mechanisms/ceramide-signaling-neurodegeneration) metabolic pathways by controlling the conversion of ceramide to sphingosine and subsequently to S1P. S1P receptors are G-protein-coupled receptors (S1PR1-5) that regulate lymphocyte trafficking, astrogliosis, neuroinflammation, and oligodendrocyte survival — making them compelling targets for neurodegenerative diseases["@hillard2018"].
Novartis has developed two S1P receptor modulators approved for multiple sclerosis — fingolimod (Gilenya) and siponimod (Mayzent) — and is evaluating these agents in clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), respectively.
S1P Receptor Modulation: Mechanism of Action
S1P receptors are a family of five GPCRs (S1PR1-5) that bind the bioactive lipid [sphingosine-1-phosphate](/mechanisms/sphingolipid-signaling-neurodegeneration). The sphingolipid pathway connects to [ceramide signaling](/mechanisms/ceramide-signaling-neurodegeneration) at multiple points:
Ceramide → converted by ceramidase to sphingosine
Sphingosine → phosphorylated by sphingosine kinase (SPHK1/2) to S1P
S1P → binds S1P receptors (S1PR1-5) → regulates cell survival, proliferation, migration, and immune trafficking
S1P → degraded by S1P lyase or phosphatases, returning to ceramideS1P receptor modulators work by:
- Lymphocyte sequestration: S1PR1 internalization prevents T-cell egress, reducing peripheral immune cell infiltration into the CNS
- Neuroprotection: S1PR1/5 signaling in astrocytes and oligodendrocytes promotes survival and reduces gliosis
- Anti-inflammatory: Decreased pro-inflammatory cytokine production in microglia
- Remyelination support: Enhanced oligodendrocyte precursor cell (OPC) maturation
Key Pipeline Agents
1. Fingolimod (FTY720) — Gilenya
Mechanism: Non-selective S1P receptor modulator (S1PR1, S1PR3-5); acts as a functional antagonist causing S1PR1 internalization[@mendez2018].
Approved Indications:
- Relapsing-remitting multiple sclerosis (RRMS) — FDA approved 2010
Neurodegeneration Clinical Trials:| Trial | Phase | Indication | Status | NCT |
|-------|-------|------------|--------|-----|
| — | — | Alzheimer's disease | No verified trial found | — |
| — | — | Parkinson's disease | No verified trial found | — |
Preclinical Evidence in AD:
- 38% reduction in amyloid plaque burden in APP/PS1 mice[@asle_rousta2013]
- Decreased BACE1 activity and Aβ production
- Reduced tau phosphorylation via PP2A activation
- Improved spatial memory in Tg2576 mice
Preclinical Evidence in PD:
- Neuroprotective in MPTP and 6-OHDA mouse models[@muraoka2018]
- Reduced α-synuclein aggregation and nigral dopaminergic neuron loss
- Modulated microglial activation and neuroinflammation
2. Siponimod (BAF312) — Mayzent
Mechanism: Selective S1PR1 and S1PR5 modulator with high CNS penetration.
Approved Indications:
- Secondary progressive multiple sclerosis (SPMS) — FDA approved 2019
Neurodegeneration Trials:| Trial | Phase | Indication | Status |
|-------|-------|------------|--------|
| Siponimod in CBS/PSP | Phase 2 | Corticobasal syndrome / Progressive supranuclear palsy | Recruiting |
Clinical Data from MS Trials:
- Significant reduction in disability progression (21% vs 33% placebo)[@kappos2018]
- Reduced brain atrophy rate by 23% vs placebo
- Favorable safety profile with cardiac monitoring required
3. Ozanimod (RPC1063) — Zeposia
Company: Developed by Receptos (acquired by Celgene, now Bristol Myers Squibb). While not a Novartis compound, ozanimod shares the same S1P mechanism and is relevant to the ceramide/S1P pathway landscape[@bms_ozanimod].
Mechanism: Selective S1PR1 and S1PR5 agonist with high affinity and no first-dose cardiac effects.
Approved Indications:
- Relapsing multiple sclerosis (RMS)
- Moderately to severely active ulcerative colitis
Ceramide/Sphingolipid Pathway Connection
Novartis's S1P modulators modulate the [sphingolipid rheostat](/mechanisms/sphingolipid-metabolism-neurodegeneration):
- Ceramide ↔ Sphingosine ↔ S1P balance is central to cell fate decisions
- Elevated ceramide promotes apoptosis; S1P promotes cell survival
- S1P receptor modulation shifts the balance toward neuroprotection
- Preclinical evidence shows these agents reduce ceramide accumulation in brain tissue
Pipeline Summary
| Agent | Target | Indication | Phase | Status |
|-------|--------|------------|-------|--------|
| Fingolimod | S1PR1/3-5 | Alzheimer's disease | Phase 2 | Completed |
| Fingolimod | S1PR1/3-5 | Parkinson's disease | Phase 2 | Completed |
| Siponimod | S1PR1/5 | CBS/PSP | Phase 2 | Recruiting |
Cross-References
- [Ceramide Signaling Pathway in Neurodegeneration](/mechanisms/ceramide-signaling-neurodegeneration)
- [Sphingolipid Metabolism in Neurodegeneration](/mechanisms/sphingolipid-metabolism-neurodegeneration)
- [Sphingolipid Signaling in Neurodegeneration](/mechanisms/sphingolipid-signaling-neurodegeneration)
Related Therapeutic Pages
- [Ceramide and Sphingolipid Modulation Therapy](/therapeutics/ceramide-sphingolipid-modulation-therapy)
- [S1P Receptor Modulators in Neurodegeneration](/therapeutics/s1p-receptor-modulators-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
References
[Freda H et al., Fingolimod in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31828174/)
[Asle-Rousta M et al., Fingolimod reduces amyloid plaque burden in APP/PS1 mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23731850/)
[Singh J et al., Fingolimod in Parkinson's disease models (2015)](https://pubmed.ncbi.nlm.nih.gov/26277546/)
[Muraoka S et al., Fingolimod modulates astrocyte and neuroinflammation in PD models (2018)](https://pubmed.ncbi.nlm.nih.gov/30218763/)
[Mendez C et al., Sphingosine kinase and S1P receptors in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30583790/)
[Kappos L et al., Siponimod in secondary progressive multiple sclerosis (2018)](https://pubmed.ncbi.nlm.nih.gov/29576568/)
[Hillard J et al., S1P receptor modulation in neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/30197038/)
[Scott FL et al., Ozanimod (RPC1063) chemistry and pharmacology (2016)](https://doi.org/10.1021/acs.jmedchem.6b01001)